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ABSTRACT
Muscle cramps are characterized by sudden, painful 
involuntary contraction of the muscles. The cramps 
sometimes become disabling and the prevalence is 
more in the elderly. The etiology of the cramps are 
diverse and some time the cramps are idiopathic. There 
are many underlying pathophysiological disorders like 
hypocalcemia, hypomagnesemia, hypothyroidism, and 
hepatorenal dysfunction which causes muscle cramps. 
Similarly, diabetes mellitus results in muscle cramps 
due to electrolytic imbalance, hypoglycemia, periphe­
ral arterial insufficiency, and neuropathies. Persistent 
muscle pain in diabetic patients degrades the quality 
of life of those patients. Although the pathophysiology 
and etiology of the muscle cramps are understood to 
some extent, the same is less explored from diabetes 
mellitus perspective. Hence the objective of this review 
is to explore the underlying factors responsible for 
muscle cramps in diabetes so that proper strategy for 
pharmacotherapy can be made to manage this condi­
tion. (Clin Diabetol 2019; 8, 6: 310–317)
Key words: muscle cramps, diabetes mellitus, 
hypocalcemia, hypomagnesemia
Introduction
Muscle cramps are generally painful involuntary 
contraction of muscles caused due to ectopic discharge 
from nerve terminals or nerves [1]. These muscle cramps 
differ from benign to sometime disabling. Hence, a de-
tailed history and neurological examination is indispen-
sable to identify diverse etiology of the muscle cramps 
[2]. According to a cross sectional study on 365 older 
outpatients in UK, 50% of them reported frequent mus-
cle cramps [3]. In another review 56% out of 515 old 
patients reported to have muscle cramps at least once 
in a week [4]. However, a very limited epidemiological 
data is available on the prevalence of muscle cramps in 
patients with diabetes and in general population [5]. 
A demographic study conducted on diabetic patient in 
Toronto revealed, a 75.5% of type 2 diabetic and 57.5% 
of type 1 diabetic patients encountered muscle cramps 
[6]. In the above study, diabetic neuropathy was found 
to be the most important independent risk factor for 
muscle cramps. Bharucha et al. in their door-to-door 
survey analysis in a parsi community found diabetes to 
be the most common cause for non-compressive neu-
ropathy [7]. The high rate in Parsis is probably related 
to aging population, and in urban slum, it may be due 
to nutritional and adverse environmental factors and 
needs further study. Saha et al. in his study showed 
an increase in age and sex specific prevalence of neu-
rological disorders in both sexes although there was a 
minor dip in female population in their fourth and fifth 
decades [8]. A population-based survey by Gouri-Devi 
et al. showed a two times high rate of neurological 
disorders as compared to urban parts but the reasons 
could not be determined [9].
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In diabetes mellitus, muscle cramps are a common 
symptom which may occur due to electrolytic imbal-
ance, hypoglycemia, peripheral arterial insufficiency 
and neuropathies. These cramps generally occur in the 
lower extremities and the patients mostly experience 
it during night. The symptoms range from cramping 
muscle pain to burning sensation. Muscle infarction is a 
rare cause of acute muscle pain in diabetic patients [10]. 
The cramp-fasciculation and peripheral neuropathies 
are closely associated with muscle cramps [2]. Besides, 
hypocalcemia, hypomagnesemia, hypothyroidism, and 
hepatorenal dysfunction may also contribute to muscle 
cramps. Sometime these muscle cramps are idiopathic 
which vary in presentation from subject to subject. 
There are only few studies available which completely 
address the issue of muscle cramps in relation with 
diabetes. Hence, the objective of this review is to dis-
cuss completely on the pathology, cause and possible 
treatment modalities of muscle cramps with special 
attention on diabetes.
Pathophysiology and etiology  
of muscle cramps
Various theories have been postulated to explain 
the pathophysiology of muscle cramps [11]. 
General pathophysiology of cramps 
1. Old theories
Psychosomatic theory 
The psychosomatic disorder causing muscle cramps 
is one among the major theories postulated by olden 
French and German neurologist. As per Féré, muscle 
cramps result due to heavy exercise, nervousness, neu-
rasthenia, hysteria or epilepsy [12].
Vascular theory
In the 1920s, vascular insufficiency during muscle 
contraction was believed to be the major cause of muscle 
cramps. Accumulation of lactic acid was believed to cause 
persistent involuntary contraction and muscle cramps 
[13]. Vascular theories were believed until the mid-1980s 
in central Europe. However, these theories are rejected by 
Santler, based on clinical common sense [14, 15].
Deformity theory
Static origin of muscle cramps is one among the 
theories postulated in the past responsible for muscle 
cramps. Muscle cramps in feet and calves’ muscle are 
believed to be due to static deformities of the back, 
the pelvis, legs and feet [16, 17]. As rest removes the 
sources of irritation, this theory supports the argument 
of healing effect of the rest on exercise induced muscle 
cramps [18].
Myogenic theory
Another theory is postulated by Strümpell [19] who 
said that muscle cramps have a myogenic origin, like 
myotonia. He postulated that the contraction of the 
sarcoplasma in the muscle fibrils cause muscle cramps. 
Hence this pain resembles violent colics. This view was 
opposed by Grund, 1971 [20].
ATP deficiency theory
It is a well-known fact that muscle cramps occur 
due to lack of relaxation of skeletal muscles. Upon 
relaxation of skeletal muscles, myosin fibers get dis-
sociated from actin. For this process to take place ATP 
must get attached to myosin. A paucity of ATP produces 
insufficient dissociation of myosin from actin [21]. In 
one recent study, L-carnitine proved to improve the 
prognosis cirrhotic cramps [22].
2. New theory
Neural origin theory
Very recent theory on muscle cramps was neural 
origin of cramps. A strong clinical association exists 
between muscle cramps and lower motor neuron dis-
eases like amyotrophic lateral sclerosis, neuropathy and 
radiculopathy. These are not associated with upper mo-
tor neuron or muscular disease. Spinal reflex produced 
due irritation of intramuscular sensory nerve endings by 
toxins like arsenic, alcohol, diabetes mellitus and cholera. 
This leads to prolonged irritation of anterior horn nerve 
cells there by result in muscle cramps [23]. In another 
study, Klimke reported sympathetic stimulation of ske-
letal muscle by creatine or neurovegetative irritation is 
a major factor of muscle cramps [24]. The loss of motor 
neurons with increased age leads to muscle cramps in 
older people [2]. This result is espoused by a case-control 
study where older subjects with nocturnal cramps found 
to have lesser lower limb muscle-strength compared 
to their counter parts without nocturnal cramps [25]. 
Tendon shortening in advanced aged individuals due to 
long immobility leads to excitation of nerve terminals 
which in turn leads to the development of cramps.
Site of origin
The site of origin of the muscle cramps plays pivotal 
role in pathophysiology of muscle cramps. Many studies 
have suggested that muscle cramps result from a rapid 
penetrative firing of motor unit action potential which 
are set at a rate much higher than those needed for 
involuntary contractions. This is due to spontaneous 
discharges of motor nerve ending rather than a central 
or muscular origin [2]. The factors which contribute to 
muscle cramps include excitability of anterior horn cells 
or the intramuscular motor nerve endings. 
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Etiology of muscle cramps
Table 1 is a crisp presentation of etiology of muscle 
cramps. Table 1 summarises few of the huge number 
of etiologies of muscle cramps in a diabetic population 
and it has been found that most of them are either due 
to idiopathic reason or due to underlying peripheral 
neuropathy [6, 31]. A study of outpatient veterans 
reported leg cramps in 75% of those with peripheral 
vascular disease, 63% of those with hypokalemia, and 
62% of those with coronary artery disease [5].
There is a famous case report of a 56 year old 
poorly controlled type 2 diabetes who experienced 
severely painful muscle cramps of bilateral upper and 
lower extremity shortly after analogue insulin injection 
the cause of which had been attributed to a 16% drop 
in potassium due to insulin injection from baseline on 
top of an already existing neuropathy in that patient 
[26]. A similar finding was observed long back in Duke 
University Medical Centre way back in 1992 [32]. 
Diabetic neuropathy and nephropathy were re-
ported to have been associated with high incidence of 
muscle cramps but neuropathy seems to be an inde-
pendent risk factor as well as the type of diabetes like 
type 2 > type 1 [6]. Towards the end of hemodialysis 
one third of the patients experience muscle cramps [33] 
which gets subsided by volume expansion with hyper-
tonic dextrose or saline solution. Intentionally changing 
the sodium concentration of the dialysis fluid during 
the dialysis is sometimes used to preserve the plasma 
volume towards the end of the dialysis. This process 
reduces the incidence of muscle cramps in some cases 
[34, 35]. It is also known that any acute extra cellular 
fluid volume contraction cause muscle cramps. This 
occurs during excessive vomiting, diarrhoea or exces-
sive sweating or diuretic therapy. About 60 percent of 
patients with cirrhosis reportedly have leg cramps, most 
of whom are older patients with advanced disease [29]. 
Chronic venous insufficiency also results in cramps but 
strangely enough the treatment has not lead to the 
slowing down of the course of muscle cramps [11]. 
Nerve damage from cancer treatment may be a cause 
of legs cramps, with a small study demonstrating that 
leg cramps were present in 82 percent of patients with 
cancer [30].
Muscle cramps caused due to adverse event of 
number of drugs, however, very few drugs reported 
to have caused leg cramps. The medication with in-
travenous iron source, raloxifene (Evista), naproxen 
(Naprosyn), conjugated estrogens, and teriparatide 
(Forteo) produced very low incidence of leg cramps 
[31]. Besides, clonazepam (klonopin), celecoxib (Cele-
brex), and gabapentin (Neurontin) also produce leg 
cramps, although they are prescribed for treatment 
of muscle cramps. It is also believed that diuretics like 
hydrochlorothiazide cause leg cramps [36].
Muscle cramps are associated with various diseases 
which cause damage to lower motor neurons includ-
ing amyotrophic lateral sclerosis (ALS) [37], peripheral 
nerve injury [38], and polyneuropathies [39]. Cramps 
are more common in the above diseases compared to 
other lower motor neuron ailments although the cause 
is not very clear till date. 
Due to metabolic changes during pregnancy 30% 
of women in their third trimester of pregnancy experi-
ence muscle cramps [40].
Pathophysiology of muscle cramps  
in diabetes
Data is sparse on explaining the pathophysiology 
of muscle cramps in diabetics and more specifically 
why it actually happens mostly in early morning hours. 
In a rodent model study on C57BL/6 male mice, it was 
seen that mice quadriceps centralized nuclei and cas-
pase 3 protein increased significantly reflected by a p 
value of < 0.05 in both cases [41]. The data suggested 
that diabetes induced muscle damage by promoting a 
profibrotic profile. In another human study on muscle 
biopsy it was found that rate of ADP depletion with 
rest (p = 0.008) and oxidative phosphorylation (p = 
0.046) in type 2 diabetic gastrocnemius muscle was 
impaired as evidenced by 31phosphorus magnetic reso-
Table 1. Etiology of muscle cramps (decreasing frequency 
in terms of association to diabetes) [11, 26–30]
Sl. No Cause
1 Idiopathic
2 Peripheral neuropathy
3 Peripheral vascular diseases
4 Cardiovascular disorders
5 End stage renal disease on maintenance  
hemodialysis and acute electrolyte changes
6 Insulin induced acute drop in serum  
potassium levels 
7 Cirrhosis of liver
8 Venous insufficiency
9 Cancer chemotherapy
10 Drug induced — intravenous iron sucrose,  
raloxifene, conjugated estrogens, naproxen,  
teriparatide, daclizumab, levosalbutamol, etc.
11 Neurological disorders like amyotropic lateral  
sclerosis, parkinsonism, etc.
12 Lumbar canal stenosis
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nance spectroscopy [42]. L-carnitine deficiency might 
also play an important role in diabetic mitochondrial 
dysfunction which has been frequently associated with 
muscle cramps as the deficiency has been linked to 
insulin resistance [43].
Mitochondrial dysfunction is another key player 
in causing muscle cramps in diabetics [44]. One study 
revealed that almost two thirds of diabetic patients 
suffer from muscle cramps and often they seem to 
harbour diabetic neuropathy [6]. Another important 
aspect is a high prevalence of dyslipidemia in diabetic 
patients for which statins have to be used and this sta-
tin cause a reduction of coenzyme Q10 which is often 
responsible for the muscle cramps [45, 46]. The other 
suggested etiologies for muscle cramps in diabetics are 
hypoglycemia, peripheral arterial disease, neuropathy 
or electrolyte imbalances [47]. In an epidemiological 
study it was seen that neuropathy and not nephropathy 
as well as type of diabetes (type 2 > type 1) were im-
portant independent predictors of muscle cramps [6].
Characteristic changes of muscles at molecular 
level in diabetes
Muscle related pathologies in diabetics have mul-
tiple reasons and these are summarized below.
Genetics
Gene expression alterations have been reported 
with type 2 diabetes. In a study, skeletal muscle biop-
sies taken from male subjects with type 2 diabetes, 
their first-degree relatives, and healthy controls were 
investigated at the gene expression level using the 
microarray technology [48]. An important finding in 
another study was the substantial increase in expres-
sion of genes that are involved in insulin signaling in 
skeletal muscle from first degree relatives of type 2 
diabetics, and the significant downregulation of the 
same pathway in samples of type 2 diabetic skeletal 
muscles (Table 2) [49].
Microangiopathy
Small vessels are often abnormal in the tissues 
of diabetic patients. In recent years, the center of 
attention has been focused on the capillary base-
ment lamina, which is a layer of amorphous material 
chemically resembling collagen coating the exterior 
of the endothelial cells. There has been widening of 
the capillary basement lamina in the skeletal muscle 
biopsies from diabetic patients. The endothelial cells 
appear unremarkable, but the basement lamina seems 
greatly widened and is often redundant and laminated 
with various materials in-between the lamina. In more 
recent years, attention has been directed to the capil-
lary basement lamina, a layer of amorphous material 
chemically resembling collagen that coats the exterior 
of the endothelial cells. This layer is located between 
the blood carrying oxygen and nutrients and the tissues. 
Widening of the capillary basement lamina in skeletal 
muscle biopsies from diabetic patients. In any event, the 
abnormal production of basement lamina appears to 
be widespread in the capillary bed of patients suffering 
from diabetes mellitus and these capillary abnormalities 
have important consequences with respect to many of 
the lesions that occur in this disease [50].
Mitochondrial dysfunction
In one recent study, it has been observed that in 
type 2 diabetic patients the muscle cramps are pro-
duced due to impaired bioenergetic capacity of skeletal 
muscle mitochondria. The study was done by taking the 
biopsy of vastus lateralis muscle from lean and obese 
nondiabetic subjects and type 2 diabetic volunteers. 
The electron microscopy view of the skeletal muscle 
revealed the presence of smaller mitochondria in type 2 
diabetic and obese volunteers compared to their lean 
counterparts (p < 0.01). Similarly, the activity of rote-
none-sensitive NADH:O2 oxidoreductase enzyme was 
reduced in type 2 diabetic skeletal muscle compared to 
the healthy subjects. Hence, it was concluded that in 
the skeletal muscle of diabetic patient the mitochondria 
lose its bioenergetic capacity. 
Table 2. Significant genetic changes in pathways/functions
Gene pathway/function p­value Remarks
First degree relatives
Insulin signalling 0.005 Up regulated
TGF-beta signalling 0.068 Up regulated
RNA splicing 0.089 Up regulated
Inorganic anion transport 0.74 Down regulated
Focal adhesion 0.14 Down regulated
Inflammatory response  
pathway
0.326 Down regulated
Type 2 diabetic patients
Protein modification 0.979 Up regulated
Cell cycle G1 to S control 
reactome
0.676 Down regulated
MAPK signalling 0.002 Down regulated
Insulin signalling 0.002 Down regulated
G-protein signalling 0.078 Down regulated
Apoptosis 0.388 Up regulated
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Skeletal muscle lipid content  
and oxidative enzyme activity
In type 2 diabetes and obese patients, a reduced 
oxidative enzyme activity, increased lipid content 
and increased glycolytic activity was observed in the 
skeletal muscle. Insulin resistant glucose metabolism 
is associated with this metabolic characteristic of the 
muscle [38].
Differential diagnosis and evaluation  
of muscle cramps
Cramps related to diabetes need to be identified 
carefully, condition which might mimic the diabetic 
cramps needs to be excluded by performing relevant 
test or checking the medical history of the patient. 
Upon exclusion of the etiologies and symptoms men-
tioned in Table 3, the muscle cramps related to diabetes 
are confirmed [51]. 
Treatment of muscle cramps
It is indispensable to detect underlying cause of 
structural and metabolic disorder leading to muscle 
cramps in diabetic patients. Different treatment strate-
gies can be followed to treat acute and chronic pain 
in diabetes. In case of acute pain non-pharmacological 
strategies are adapted. Stretching or lengthening the 
cramps muscle stops most of the acute cramps [52, 53].
In the recent past, various clinical trials were con-
ducted to check the safety and efficacy of various drugs 
and nutraceuticals in diabetes induced muscle cramps. 
Miller et al., in the year 2001, conducted a phase III clini-
cal trial to study the effect of gabapentin (a glutamate 
blocking drug) on patients with ALS. It was a double-blind 
randomized controlled trail on 204 patients with ALS. 
The result of this trial was compared with the phase II 
trial of the same drug conducted in smaller population 
and for a shorter period of time [54, 55]. Despite the 
positive phase II trial report, the phase III trial failed to 
prove the therapeutic efficacy of gabapentin in patients 
with ALS. The encouraging phase II data was believed 
to be due to by chance. Finally, it was concluded that 
gabapentin had no therapeutic effect on patients with 
ALS. In another study, 28 elderly patients were enrolled 
to check the efficacy of vitamin B complex (including 
vitamin B6 30 mg/day) in reducing the nocturnal leg 
cramps. After three months of treatment (vitamin B 
complex capsule TID) 86% of patients experienced 
remission from muscle cramps [56]. The patients were 
not known to be suffering from any vitamin deficiency 
compared to placebo group.
Table 3. Differential diagnosis of leg cramps
Condition Clinical features Diagnosis Treatment
Claudication Aching, sometimes cramping, deep pain 
brought on by exercise; relieved with rest
History
Atherosclerotic risk factors
Ankle-brachial index
Radiographic studies
Risk factor modification
Graded exercise
Invasive interventions
Exercise-associated  
muscle cramping
Painful cramps during or immediately after 
exercise
Palpable muscle tightening
History Graded exercise and 
stretching
Hypnic myoclonus Sudden involuntary jerking at the onset of 
sleep
May awaken the patient
History (from bed partner) Reassurance
Myositis, myalgias Deep, aching pain unrelated to exertion
Weakness and poor exercise tolerance
Often occurs in legs, but can affect any 
muscle
History
Elevated creatinine kinase 
levels (myositis)
Statin use
Evaluation for polymyositis 
and dermatomyositis
Treat underlying cause
Discontinue statin
Periodic limb movement 
disorder
Nonpainful, repetitive, rhythmic, slow  
dorsiflexion of toes, knees, and hips  
during sleep
Daytime fatigue
Patient is unaware
History (from bed partner)
Polysomnography
Sleep modification, includ-
ing medications
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Naftidrofuryl, a vasodilator was studies in a cohort 
of 14 subjects suffering from rest cramps (night cramps). 
The effect of this drug on cerebrovascular and peripheral 
vascular disease was well established before. However, 
Young and Connolly in the year 1993, could establish its 
significant remedial effect on the rest cramps [57]. Naf-
tidrofuryl could significantly reduce cramps frequency 
in the patients (p < 0.004) in this double-blind placebo-
-controlled trial. This drug enhances the utilization of 
glucose and oxygen in peripheral vascular disease and 
protect brain parenchyma during anoxia.
Diltiazem hydrochloride, a calcium channel blocker, 
used in hypertension was studied for the management 
of muscle cramps. In this cross-over double-blind study, 
13 patients who experience two or more cramps per 
week were treated with 30 mg of diltiazem hydrochlo-
ride. There was a significant (p < 0.04) reduction in the 
number of cramps in drug treated group compared to 
placebo [58]. This study proved the therapeutic poten-
tial of diltiazem in the management of muscle cramps.
As per recommendation of American Academy of 
Neurology, vitamin B complex, calcium channel blockers 
such as diltiazem and naftidrofuryl are effective and can 
be considered for use in the management of muscle 
cramps (level C). It has also been recommended to avoid 
the use of quinine derivatives (level A) owing to their 
potential toxicity [59]. However, quinines can be used 
for an individual therapeutic trial upon confirmation 
on the management of potential adverse effect if any. 
Oxidative stress was believed to have an effect 
on the development of insulin resistance [60] and in 
some studies treatment with antioxidants seemed to 
improve glycine control in type 2 diabetic patients by 
scavenging the reactive oxygen species [61, 62]. In 
one recent study, high dose of vitamin E supplementa-
tion found to improve insulin action by reducing the 
plasma fasting insulin and glucose levels. There was 
also substantial decline in cellular oxidant stress and 
inflammatory activity [63]. Hence, in case of diabetic 
muscle cramps vitamin E can be used as supplement 
with the first-line treatment.
The effect of L-carnitine supplementation in the 
management of cirrhotic muscle cramps is discussed in 
the previous section. However, in a recent study [64], 
L-carnitine supplementation (600 mg/day PO for 4 mon-
ths) was found to improve the quality of life of diabetic 
patients suffering with muscle cramps. Hence, L-carnitine 
supplementation can be considered as an ideal strategy 
to manage muscle cramps in diabetic patients.
Role of ubiquinone
Two forms of Co-enzyme Q10 (CoQ10) namely 
ubiquinone (oxidized form) and ubiquinol (reduced 
form occurs naturally in human body [65] and other 
anaerobic organisms. The production of this enzyme 
reaches at its highest during mid-twenties and gradu-
ally declines with age. The concentration of this enzyme 
gets reduced to 50% by the time people reach 60 years 
of age [66]. In the recent past, it was reported that 
a significant decline in the level of CoQ10 in patients 
with type 2 diabetes is correlated with an increased 
plasma glucose level, HbA1c and other oxidative stress 
markers [67].
The rate limiting enzyme 3-hydroxy-3-methylglu-
taryl-CoA reductase (HMGCR) is instrumental in the 
mevalonic acid path way, cholesterol biosynthesis 
and synthesis of CoQ10.The inhibition of HMGCR, 
serious muscle injuries (e.g. myopathy, myositis and 
rhabdomyolysis) are the adverse events of statins (e.g. 
atorvastatin) used in the treatment of hypercholes-
terolemia in type 2 diabetes [68, 69]. Hence, CoQ10 
supplementation for statin induced muscle symptoms 
have opened a new avenue in the complementary 
management of statin-induced myopathy in type 2 
diabetic patients [70].
Special focus of muscle cramps  
in diabetics
The complication of muscle cramps is a very 
common one in our type 2 diabetic patients and the 
treatment should be addressed to the underlying 
cause if possible or else it should be treated as per 
the above regimen of use of co-enzyme Q10 as part 
of idiopathic etiology. A summary of treatment in 
diabetics is shown below in Table 4 as per the major 
contributing factors towards cramps. 
Table 4. Causes and treatments of muscle cramps in diabetics
Cause Treatment 
Peripheral neuropathy Standard treatment for neuropathy with tricyclic antidepressants, pregabalin, gabapentin
Peripheral vascular diseases  
and cardiovascular diseases
Stenting if needed, smoking cessation, cilostazol, standard treatment with statins and  
aspirin and clopidogrel
ESRD on maintenance hemodialysis Changing the sodium concentration of the dialysis fluid during the dialysis; treating  
underlying co-existent neuropathy
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Conclusion
Muscle cramps in diabetes reduce the quality of 
life of patients. Diagnosis of muscle cramps in diabetic 
patients is a common problem in clinical practice. How-
ever, the mechanism and underlying cause is less well 
understood till date. Hence, the diagnosis of muscle 
cramps should prompt the physician to look for any 
associated comorbidities like peripheral neuropathies, 
metabolic disorders, cirrhosis, immune mediated myosi-
tis, and ALS etc. Although the availability of treatment 
is less, the physician should carefully plan the treatment 
protocol to manage the cramps thereby improve the 
quality of life of patients living with diabetes.
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